To Be or Not to Be: The Role of CD56 in Multiple Myeloma

Posted by

Oncotarget

Oncotarget published this trending editorial in Volume 14, entitled, “To be or not to be: the role of CD56 in multiple myeloma" by the researchers from the Department of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH. DOI - https://doi.org/10.18632/oncotarget.28350 (PDF Download) Correspondence to - : Francesca Cottini - Francesca.cottini@osumc.edu Paper Intro Optimal management of Multiple Myeloma (MM), a disorder of clonal malignant plasmacells (PCs), is hampered by the lack of strategies to treat specific subsets of patients. Despite genetic, epigenetic, and mutational heterogeneity, every patient still receives similar regimens without accounting for this variability. This can lead to unsatisfactory or short-lasting responses especially in the relapsed settings or in patients with high-risk chromosomal abnormalities such as t(4;14), 1q21+, or deletion(17p) [1]. MM cells express on their surface a variety of antigens, which help to discern normal reactive PCs from malignant MM cells [2]. These antigens are also targets for monoclonal antibodies, bispecific engagers, or chimeric T/NK cellular therapy [3, 4]. Among them, there is CD56 or NCAM1 (Neuronal Cell adhesion molecule 1), a glycoprotein normally present in neurons, Natural Killer (NK), and T cells, but aberrantly expressed in more than seventy percent of patients with MM [5]. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28350 Keywords - myeloma, targeted therapies, CD56, signaling About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957